|
Silver as
silver nitrate, colloidal silver or silver sulphadiazine
cream has been a choice antibiotic for wound care for
many generations and numerous clinical studies have
substantiated its merits in treating venereal
infections, warts, chronic ulcers and surgical
incisions. Clearly, after a highly successful meeting of
the European Tissue Repair Society in Cardiff in 2001
and the publication of three issues of 'The Silver
Supplement' to the British Journal of Nursing, it is
clear now that we have entered the new phase of
'sustained-silver release dressings'.
Recent
advances in biotechnology and original research have
provided unique opportunities to develop dressings which are
closely tailored to the type of wound to be treated. They
are biocompatable and are proving to be of great benefit in
advancing healing in difficult wounds whilst alleviating
patient discomfort and impaired mobility. At least ten new
sustained silver-release dressings have reached late stages
in development or are presently marketed in Europe and
elsewhere. They vary greatly in composition but are
variously designed to cope with moderately to heavily
exudating wounds with unsociable odours, and pain and
discomfort. Silver is presented to the wound as a broad
spectrum antibacterial with claims for efficacy in the
elimination of Gram positive and Gram-negative bacteria,
yeasts/fungi, and the methicillin-resistant Staphylococcus
aureus and vancomycin-resistant infections. Other materials
present include polyurethane foam or lamina, hydro-colloids,
charcoal-containing materials, nylon cloth or other
substances to control odours and excessive wound exudates
whilst maintaining a suitably moist environment to maximise
healing. The term 'nanocrystalline' silver has been
introduced and is held to represent a new entity in wound
management.
Silver as an Antibacterial
Agent
As a metal, silver is relatively
inert and poorly absorbed by mammalian or bacterial
cells. However, in the presence of wound fluids or other
secretions, it readily ionises and becomes highly
reactive in binding to proteins and cell membranes. The
silver ion (Ag+) is absorbed by the bacterial or yeast
cells and is lethal in sensitive strains.
The biocidal effects of silver are
complex, and different organisms respond to silver to
varying extents. Evidence provided from the development
of silver:copper filters in the sterilization of
hospital water systems, suggests that silver is
accumulated preferentially in sensitive bacterial
strains and that concentrations of 105-107 ions per cell
are lethal.
Early pharmacologists coined the term oligodynamic to
refer to the ability of sensitive bacteria to absorb and
concentrate Ag+ from dilute solutions. They suggested
that the lethal concentration of ion in a cell was
equivalent to the number of bacterial cell enzymes
present.
Studies
designed to evaluate the efficacy of silver nitrate,
silver sulphadiazine or the newer sustained silver
release dressings, have routinely assessed their effect
on the type and severity of infections present in
wounds. Few have looked at the mechanism(s) of
bactericidal action or discussed how or why different
organisms exhibit varying sensitivity to the silver ion.
Microbiological studies illustrate that the 'activated'
silver ion (Ag+ or other species) can exert its
lethality through action on the bacterial cell membrane
(envelope) or binding to and inactivating intracellular
proteins/enzymes and nuclear DNA.
Many studies have examined the biocidal action of silver
ion and silver-release dressings on species of bacteria
or yeasts in vitro. An example is provided by a
bioactive glass containing silver oxide as an
antibacterial developed for use in dentistry or
orthopaedic medicine. This was highly effective against
Pseudomonas aeruginosa, Staphylococcus aureus and E.coli
at concentrations of 0.05-0.2 mg/ml, Ag+ leaching from
the glass matrix was the active agent rather than any
other effect (changes in pH, ionic strength, etc.)
attributable to other biomaterials present. In vitro
studies have provided evidence that this bacticidal
effect is attributable largely to the binding of the
silver ion to free sulphydryl groups in the bacterium or
on its surface. Thus silver sulphadiazine and two other
silver-containing products were shown to inhibit the
growth of Candida albicana or E.coli through
inactivation of the enzyme phosphomannose isomerase.
Where the enzyme was mutated to replace the free cystine
moiety with alanine (lacking -SH groups), inhibition was
not seen.
More substantive information on the bactericidal action
of silver relates to its accumulation in the bacterial
cells and its opportunity to interact with the cytosolic
proteins, mitochondrial enzymes and nuclear DNA or RNA
synthesis. Substances in the medium (or it the wound
bed) that chelate free silver ion or precipitate it as
an insoluble sal, inhibit bacteriostasis. Thus sodium
chloride (as possible found in wound exudates) has been
shown to inhibit the antibacterial action of silver
nitrate by precipitating the silver as insoluble silver
chloride. On the other hand, EDTA or EGTA, have been
shown to enhance the biocidal effect of silver nitrate,
possibly through chelating silver binding substances.
Silver resistant strains of bacteria are a continuing
problem in wound care despite many claims in the
literature to the contrary. Accumulating evidence
indicates that the bactericidal activity of silver is
directly related to the amount of silver accumulating
within the bacterial cell and its ability to denature or
otherwise impair physiological processes.
Silver-sensitive strains of Pseudomonas stut-zeri have
been shown to produce a higher emission of hydrogen
sulphide gas than the resistant strains. Slawson et al
(1990) reviewing the interactions between bacteria and
silver emphasised the influence of silver on
mitochondrial activity and other energy dependant
processes.
They drew attention to the role of
plasmids (cytoplasmic particles) in bacterial
resistance. Further work revealed that silver resistance
is related not only to the existence of plasmids in the
bacterial cell, but their structure and type. Starodub
and Trevors (1989) demonstrated two large plas-mids in
silver resistant strains of E.coli isolated from a burns
wound patient and their propensity to bind silver ion.
They noted that by heating, they could alter the silver
binding properties of these plasmids and influence
bacterial resistance to silver. Transmission electron
mi-croscopy and energy dispersive X-ray analysis of
whole cell mounts from actively growing cultures
confirmed that resistant strains did not accumulate
silver whereas the sensitive strains exhibited numerous
electron dense particles. In this strain of E.coli at
least, the plasmid coded 'pJTI (83kb) seemed to be
primarily responsible for silver resistance. Similar
patterns of plasmid-modulated silver uptake are known to
control the sensitivity of bacteria like Acenitobacter
baumannii and Salmonella sp., but further work is
urgently needed to examine mechanisms of silver
sensitivity in bacterial and fungal strains commonly
found in skin wounds and ulcers.
Silver and the Skin Wound
The literature is replete with
clinical trials purporting to shown the benefits of
silver therapeutics and silver-release dressings on
wound repair and regeneration through its antimicrobial
efficacy. Little is published, however, to show how the
released silver ion influences the wound bed, or to what
extent it is metabolised or deposited in the tissue.
Nevertheless, silver is absorbed into the wound site,
some serving an antimicrobial function, with the
remainder being taken up by cells at the wound margin or
diffusing into the circulation. It maybe that some of
the silver ion is absorbed into the epidermis in the
form of a reservoir and then released into the
surrounding tissues, but there is evidence that silver
uptake tends to be higher in partial thickness wounds
where granulation tissue is more extensive.
In the wound bed, silver ion is
biologically active and avidly combines with proteins,
cell surface receptors (and sulphydryl groups) and wound
debris. A contraindication for silver nitrate use in
wound prophylaxis, is its profound ability to stain
everything black. Although silver nitrate is an
effective antibacterial agent and is still available,
the tissue discoloration is usually unacceptable these
days except in the treatment of severe burns. Although
silver sulphadiazine and the new sustained-silver
release dressings liberate silver ion into the wound
bed, discolouration of the tissue is rarely a problem
with silver sulphadiazine, and has not been recorded so
far with products like Acticoat, Actisorb, Contreet,
Arglaes or Avance. The reasons for this are not clear at
the moment, but possibly relate to the nature/species of
silver ion released and its reactivity with proteins in
the wound bed.
Absorption of silver from wound
care products and dressings by cells of the wound margin
is not documented in most clinical studies, but regular
mention is made of improved patterns of re-epithelialisation,
wound closure and healing. This suggests that the silver
ion is having a direct effect on the regenerating
epidermis, or it is enhancing the local microenvironment
in some way to promote the healing process. Reduced
wound pain and patient discomfort might suggest that the
silver is acting also on the inflammatory/granulation
tissue phase of wound repair and upon the
polymorphonuclear cells entering the site. However, we
do know through experimental and clinical work, that
silver permeating into the wound bed is taken up by
epidermal cells at the wound margin and is accumulated
in the wound debris and passes into the peripheral
circulation to be deposited in the liver and kidney,
with some voided in the urine.
Experimental studies in laboratory animal models have
greatly aided our understanding of the action of silver
in the wound. Porcine burn-like wounds, for example,
have been shown to absorb silver from silver
sulphadiazine leading to the preservation of 'viable'
dermal tissue, improved wound contraction and activation
of dermal myo-cytes (fibroblasts). In rat and guinea pig
wounds, silver nitrate and silver sulphadiazine advanced
wound repair and neovascularisation without obvious
contraindica-tions.
Improved healing in rat wounds exposed to silver nitrate
or silver sulphadiazine has prompted research into the
mechanism of action of the silver ion in epithelial
cells. Evidence was provided through immunocytochemical
evaluation of key metal-binding metallothioneins, to
show that silver induced these proteins and enhanced the
local concentrations of zinc and copper. Both metals are
essential micronutrients involved in epithelial cell
proliferation. Increased zinc leading to enhanced
production of RNA and DNA-synthetases, matrix
metalloproteinases and other essential enzymes in the
wound bed are held to contribute to the improved healing
observed. Interestingly, increased calcium levels have
been observed in experimental wounds treated with
silver. The implications of this are unclear at the
moment, but we do know that calcium is an essential
component of haemostasis as Factor IV, and that
increases in calcium in the wound margin are a normal
feature of healing in acute skin wounds. Calcium serves
as a central modulator at several different levels in
wound repair and the importance of calcium gradients in
homeostasis in the skin are documented. Clearly, at a
time when calcium alginates are being introduced into
wound dressings with or without silver as an
antibacterial agents, there is an urgent need to study
the interaction between the two metals in wound repair.
Contraindications of Sustained
Silver Release Dressings
Silver has been a choice
antibacterial for use in wound dressings and
therapeutics on account of its acknowledged low
toxicity. Argyria as regularly encountered with silver
nitrate and occasionally with silver sulphadiazine, does
not seen to be a problem with Acticoat, Actisorb,
Contreet, etc. However, the principle anxiety of silver
allergy will remain. Silver allergy or hypersensitivity
does affect a small proportion of the population and
case reports relate to the use of silver nitrate as a
topical antibacterial. Although not specifically
identified so far, the possibility of allergic reactions
arising through the use of newer silver wound treatments
should be considered, and may prove a contraindication
for their use in some patients. Other complications
including leucopenia, bone marrow toxicity and renal or
hepatic damage through silver deposition, as seen rarely
with silver nitrate of silver sulphadiazine, are likely
to be of marginal significance.
Future Research and Development
Recent research and new
developments in wound dressings have provided clinicians
with greatly improved methods for treating chronic and
complicated wounds with the high risk of infections.
Whilst clinical trials provide unequivocal observations
on the advantages and benefits of the various dressings
available, from a scientific and regulatory view, it is
desirable now to investigate mechanisms of action and
the fate of the silver ion. Animal models have provided
considerable insight into mechanisms of action of silver
and other wound medicaments. These could now be
fruitfully employed to investigate such features as
silver accumulation in wound sites in relation to
healing patterns, patterns of silver metabolism in
relation to trace metals like zinc and calcium, and the
route and rates of silver excretion. Good comparative
studies of the relative benefits of Acticoat, Arglaes,
Actisorb, Contreet and Avance in a standard wound (e.g.,
the pig) can be of useful prognostic value.
Article
supplied by The EUROPEAN TISSUE REPAIR SOCIETY
|